BIM
AVEO

BlackRock Investment Management’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

BlackRock Investment Management’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-981
Closed -$9K – 4174
2016
Q1 		$9K Hold
981
– – ﹤0.01% 3668
2015
Q4 		$12K Buy
981
+90
+10% +$1.07K ﹤0.01% 3625
2015
Q3 		$11K Sell
891
-41
-4% -$593 ﹤0.01% 3665
2015
Q2 		$16K Buy
932
+89
+11% +$1.6K ﹤0.01% 3533
2015
Q1 		$12K Hold
843
– – ﹤0.01% 3600
2014
Q4 		$7K Hold
843
– – ﹤0.01% 3815
2014
Q3 		$9K Buy
843
+3
+0.4% +$38 ﹤0.01% 3723
2014
Q2 		$15K Sell
840
-17,053
-95% -$222K ﹤0.01% 3503
2014
Q1 		$268K Sell
17,893
-83
-0.5% -$1.49K ﹤0.01% 3192
2013
Q4 		$329K Sell
17,976
-364
-2% -$7.29K ﹤0.01% 3132
2013
Q3 		$378K Buy
18,340
+461
+3% +$10.6K ﹤0.01% 3041
2013
Q2 		$447K Buy
+17,879
New +$764K ﹤0.01% 2911

Other funds holding AVEO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DVC
Deer VI & Co Larchmont, New York $2.23M AUM 9.32% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

BlackRock Investment Management's AVEO Position: Q2 2016 in Review

BlackRock Investment Management sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q2 2016, closing a stake of 981 shares — an estimated $9K sold.

BlackRock Investment Management first reported a position in AVEO in Q2 2013 and held it in 12 quarters. The position peaked at $447K in Q2 2013. 48 funds tracked by Wall St. Rank hold AVEO as of Q2 2016.

  • BlackRock Investment Management reported no remaining AVEO Pharmaceuticals, Inc. position as of Q2 2016 after selling out during the quarter.
  • BlackRock Investment Management sold 981 AVEO Pharmaceuticals, Inc. shares in Q2 2016, an estimated $9K.
  • BlackRock Investment Management first reported a position in AVEO Pharmaceuticals, Inc. in Q2 2013 and held it in 12 quarters.
  • BlackRock Investment Management's AVEO Pharmaceuticals, Inc. position peaked at $447K in Q2 2013.
  • 48 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q2 2016.

Based on BlackRock Investment Management's 13F filing for Q2 2016, filed 10 Aug 2016.